Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab.
We present a case of tuberculous peritonitis in a 71-year-old woman with long-standing rheumatoid arthritis treated with adalimumab, and we review the association between antitumor necrosis factor therapy and tuberculosis. Our case illustrates that the index of suspicion of tuberculosis in these patients, even with atypical clinical features, must be very high, and underscores the need of tuberculosis screening before therapy is started.
Gutiérrez-Macías
Alfonso
A
Internal Medicine Department, Hospital de Basurto, Avenida de Montevideo, 18, 48013 Bilbao, Spain. alguma@teleline.es
Lizarralde-Palacios
Eva
E
Martínez-Odriozola
Pedro
P
Miguel-de la Villa
Felipe
F
D000068879:Adalimumab; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D005260:Female; D006801:Humans; D010538:Peritonitis / Q000382:microbiology*; D014376:Tuberculosis / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab